Completed PHASE1 INTERVENTIONAL 2-arm NCT01374620

Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel (PAL-ANGI2)

Phase I Study : Dose Escalation of Intravenous Weekly Paclitaxel in Association With Metronomic Administration of Cyclophosphamide

Sponsor: Centre Oscar Lambret

Conditions Cancer

Interventions Blood collection Cyclophosphamide Paclitaxel Paclitaxel dose escalation

Updated 5 times since 2017 Last updated: Jul 28, 2016 Started: Jun 30, 2011 Primary completion: Feb 28, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01374620, this PHASE1 trial focuses on Cancer and remains completed. Sponsored by Centre Oscar Lambret, it has been updated 5 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Oscar Lambret

Data source: Centre Oscar Lambret

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lille, France